OCWP
ARQT icon

Owl Creek Wealth Partners’s Arcutis Biotherapeutics ARQT Stock Holding History

Owl Creek Wealth Partners’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.44K Hold
55
– – ﹤0.01% 1182
2026
Q1 		$1.3K Buy
+55
New +$1.4K ﹤0.01% 1141

Other funds holding ARQT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Owl Creek Wealth Partners's ARQT Position: Q2 2026 in Review

Owl Creek Wealth Partners held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 55 shares worth $1.44K. The position accounts for ﹤0.01% of the portfolio, ranked #1182.

Owl Creek Wealth Partners first reported a position in ARQT in Q1 2026 and has held it in 2 quarters since. 249 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Owl Creek Wealth Partners held 55 shares of Arcutis Biotherapeutics worth $1.44K as of Q2 2026.
  • Owl Creek Wealth Partners left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of Owl Creek Wealth Partners's portfolio in Q2 2026, its #1182 holding.
  • Owl Creek Wealth Partners first reported a position in Arcutis Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 249 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Owl Creek Wealth Partners's 13F filing for Q2 2026, filed 20 Jul 2026.